---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/45052077.md"
description: "$Twist Bioscience(TWST.US) fell nearly 7% on Thursday, with volume more than double the average. Q4 revenue and profit both beat estimates, and FY2027 revenue guidance was raised to $550–560mn. The issue is structural: expected growth for its AI drug discovery segment in FY2027 is 69.2%, a significant slowdown from 175% in FY2026. The market premium is largely driven by the AI pharma line. While the core business is stable, the high-growth segment is decelerating, forcing valuation multiples to contract. It has already dropped 20% over the past 20 trading days; future catalysts will depend on whether AI-related orders can re-accelerate next quarter."
datetime: "2026-11-13T08:58:39.000Z"
locales:
  - [en](https://longbridge.com/en/topics/45052077.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/45052077.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/45052077.md)
author: "[好事连连](https://longbridge.com/en/profiles/27514675.md)"
generator: "portal-rs"
---

# $Twist Bioscience(TWST.US) fell nearly 7% on Thurs…


### Related Stocks

- [TWST.US](https://longbridge.com/en/quote/TWST.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**